<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <title>HELIXMITH</title>
    <link type="text/css" rel="stylesheet" href="css/reset.css" />
    <link type="text/css" rel="stylesheet" href="css/style.css" />
    <link type="text/css" rel="stylesheet" href="css/animate.css" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
</head>

<body>
    <!--wrapper-->
    <div class="wrapper">
        <!--headNavigation-->
        <div class="headNavigation headImage3 wow fadeIn">
            <!--inside-->
            <div class="inside">
                <!--menus-->
                <div class="menus">
                    <!--logo-->
                    <div class="left">
                        <a href="index.html">
                            <img src="img/logo.svg">
                        </a>
                    </div>
                    <!--//logo-->
                    <div class="right">
                        <ul class="pc">
                            <li>
                                <a href="about_1.html">
                                    About Helixmith
                                </a>
                                <div class="dropdown-content">
                                    <div class="box">
                                        <a href="about_1.html">
                                            <p>
                                                Our Company
                                            </p>
                                        </a>
                                        <a href="about_2.html">
                                            <p>
                                                Team Member
                                            </p>
                                        </a>
                                        <a href="about_3.html">
                                            <p>
                                                Locations
                                            </p>
                                        </a>
                                    </div>
                                </div>
                            </li>
                            <li>
                                <a href="vm202.html">
                                    Engensis
                                </a>
                                <div class="dropdown-content">
                                    <div class="box">
                                        <a href="vm202.html#first">
                                            <p>
                                                Overview
                                            </p>
                                        </a>
                                        <a href="vm202_dpn.html#first">
                                            <p>
                                                Engensis in DPN
                                            </p>
                                        </a>
                                        <a href="vm202_dpn.html#second">
                                            <p>
                                                Engensis in DFU
                                            </p>
                                        </a>
                                        <a href="vm202_dpn.html#third">
                                            <p>
                                                Engensis in ALS
                                            </p>
                                        </a>
                                        <a href="vm202_dpn.html#fourth">
                                            <p>
                                                Engensis in CAD
                                            </p>
                                        </a>
                                    </div>
                                </div>
                            </li>
                            <li>
                                <a href="platform.html">
                                    Early Phase Programs
                                </a>
                                <div class="dropdown-content">
                                    <div class="box">
                                        <a href="platform.html#first">
                                            <p>
                                                Neuromyon
                                            </p>
                                        </a>
                                        <a href="platform.html#second">
                                            <p>
                                                Chimericsmith
                                            </p>
                                        </a>
                                        <a href="platform.html#second">
                                            <p>
                                                Oncosmith
                                            </p>
                                        </a>
                                    </div>
                                </div>
                            </li>
                            <li>
                                <a href="botanicals.html">
                                    CERESMITH
                                </a>
                            </li>
                            <li>
                                <a href="#">
                                    News
                                </a>
                                <div class="dropdown-content">
                                    <div class="box">
                                        <a href="#">
                                            <p>
                                                News/Investors
                                            </p>
                                        </a>
                                    </div>
                                </div>
                            </li>
                            <li>
                                <a href="careers.html">
                                    Careers
                                </a>
                            </li>
                        </ul>
                        <ul class="mobile displayFlex">
                            <li>
                                <img src="img/mobile_menu_ico.svg" id="showPanel" />
                            </li>
                        </ul>
                    </div>
                </div>
                <!--//menus-->
                <!--content-->
                <div class="content subContent">
                    <h1 class="headText">
                        Engensis
                    </h1>
                </div>
                <!--//content-->
            </div>
            <!--//inside-->
        </div>
        <!--//headNavigation-->
        <!--1-->
        <div class="vm202Section marginTop50">
            <div class="first">
                <!--text-->
                <div class="text wow fadeIn" id="first">
                    <!--head-->
                    <div class="head">
                        <h1>
                            <span class="pointColorText">1.</span> Engensis in DPN
                        </h1>
                    </div>
                    <!--//head-->
                    <p>
                        Diabetic peripheral neuropathy (DPN) is one of the most commonly encountered debilitating
                        complication of diabetes, typically going with burning, tingling, throbbing, and stabbing pain.
                    </p>
                    <p>
                        About 30 million US adults have diabetes and about 28.5% of diabetics are suffering DPN, and
                        40-50%
                        of DPN patients are suffering Painful DPN . However the currently used medicines for PDPN, such
                        as
                        Lyrica and Neurontin, are palliative treatment for managing pain and are observed to have
                        serious
                        side effects and high addictiveness leading to overdose death.
                    </p>
                    <p>
                        There are 4 naturally occurring HGF isoforms, and two of them, HGF 728 and HGF 723 are the
                        main forms that activates c-Met receptor. At Helixmith, we developed a special cDNA-
                        genome hybrid gene which guarantees the simultaneous expression of HGF 728 and HGF 723
                        to maximize the biological activities of HGF.
                    </p>
                    <p>
                        There are 4 naturally occurring HGF isoforms, and two of them, HGF 728 and HGF 723 are the
                        main forms that activates c-Met receptor. At Helixmith, we developed a special cDNA-
                        genome hybrid gene which guarantees the simultaneous expression of HGF 728 and HGF 723
                        to maximize the biological activities of HGF.
                    </p>
                    <p>
                        This is a very new approach as Engensis reverses the underlying cause of neuropathy through it
                        angio- neurorestorative effect; conventional treatment options are simply managing the pain
                        symptom
                        itself. As a result, the US FDA has granted <b>RMAT (Regenerative Medicine Advanced Therapy)</b>
                        designations to this program and its Phase III clinical trial is underway in the US.
                    </p>
                    <!--<p>
                    <span class="fontBold">Clinical study information:</span><br>
                    <a href="https://clinicaltrials.gov/ct2/show/NCT02427464?term=viroMed" target="_blank">
                        https://clinicaltrials.gov/ct2/show/NCT02427464?term=viroMed
                    </a>
                </p>-->
                </div>
                <!--//text-->
                <!--safety-->
                <div class="vm202Table wow fadeIn">
                    <h2>
                        <span class="pointColorText">Safety</span>
                    </h2>
                    <!-- image-->
                    <div class="vm202Table wow fadeIn" data-wow-delay=".2s">
                        <img src="img/engensis_safety1_pc.svg" class="pc" />
                        <img src="img/engensis_safety1_mobile.svg" class="mobile" />
                    </div>
                    <!--//image -->
                </div>
                <!--//safety-->
                <!--text-->
                <div class="text wow fadeIn">
                    <p>
                        There have been no adverse events or serious adverse events directly attributed to Engensis in
                        the
                        Phase I and II clinical trials. Also, the encoded gene is indigenous, eliminating immune
                        response
                        concerns possibly attached with other gene therapies.
                    </p>
                </div>
                <!--//text-->
                <!--eff-->
                <div class="vm202Table wow fadeIn">
                    <h2>
                        <span class="pointColorText">Efficacy</span>
                    </h2>
                    <!--image-->
                    <div class="vm202Table wow fadeIn" data-wow-delay=".2s">
                        <img src="img/engensis_efficacy1_pc.svg" class="pc" />
                        <img src="img/engensis_efficacy1_mobile.svg" class="mobile" />
                    </div>
                    <!--//image-->
                </div>
                <!--//eff-->
                <!--text-->
                <div class="text wow fadeIn">
                    <p>
                        Pain scores obtained from Daily Pain and Sleep Interference Diary above show long-lasting
                        effects of
                        Engensis on pain severity. The results especially show higher improvement rate in patients not
                        on
                        pregabalin or gabapentin, proving its efficacy as a sole treatment.
                    </p>
                </div>
                <!--//text-->
                <!--divider-->
                <div class="divider"></div>
                <!--//divider-->
                <!--text-->
                <div class="text wow fadeIn" id="second">
                    <!--head-->
                    <div class="head">
                        <h1>
                            <span class="pointColorText">2.</span> Engensis in DFU
                        </h1>
                    </div>
                    <!--//head-->
                    <p>
                        Diabetic foot ulcer (DFU) is a chronic, non-healing foot ulcer, a major complication of both
                        diabetes and peripheral arterial disease (PAD) caused by impediment of the wound healing
                        process.
                    </p>
                    <p>
                        Over 6.5 million people in the US alone have chronic, non-healing foot ulcers, and many of them
                        have
                        peripheral neuropathy, which accompanies numbness or pain in legs and arms. The market size for
                        DFU
                        had grown up to 3.6 billion in 2017. However, current treatments are limited to wound care
                        dressings
                        or pain management, and 25% of wounds progress to the extent that requires amputation.
                    </p>
                    <p>
                        Engensis is currently under development targeting chronic DFU and plans to approach as a
                        fundamental treatment that can heal the ulcer by supplying sufficient blood through new blood
                        vessel formation around the occluded or narrowed blood vessels towards lower extremities.
                    </p>
                </div>
                <!--//text-->
                <!--safety-->
                <div class="vm202Table wow fadeIn">
                    <h2>
                        <span class="pointColorText">Safety</span>
                    </h2>
                    <!--image-->
                    <div class="vm202Table wow fadeIn" data-wow-delay=".2s">
                        <img src="img/engensis_safety2_pc.svg" class="pc" />
                        <img src="img/engensis_safety2_mobile.svg" class="mobile" />
                    </div>
                    <!--//image-->
                </div>
                <!--//safety-->
                <!--text-->
                <div class="text wow fadeIn">
                    <p>
                        There have been no adverse events or serious adverse events directly attributed to Engensis in
                        the
                        Phase I and II trials. The excellent safety profile is in line with expectations as Engensis is
                        locally injected with no systemic exposure. Also, the encoded gene is indigenous, eliminating
                        immune
                        response concerns possibly attached with other gene therapies.
                    </p>
                </div>
                <!--//text-->
                <!--eff-->
                <div class="vm202Table wow fadeIn">
                    <h2>
                        <span class="pointColorText">Efficacy</span>
                    </h2>
                    <!--image-->
                    <div class="vm202Table wow fadeIn" data-wow-delay=".2s">
                        <img src="img/engensis_efficacy2_pc.svg" class="pc" />
                        <img src="img/engensis_efficacy2_mobile.svg" class="mobile" />
                    </div>
                    <!--//image-->
                </div>
                <!--//eff-->
                <!--text-->
                <div class="text wow fadeIn">
                    <p>
                        Both low dose and high dose group patients showed significant changes in their ulcers, either
                        completely healed or decreased in their size.
                    </p>
                </div>
                <!--//text-->
                <!--divider-->
                <div class="divider"></div>
                <!--//divider-->
                <!--text-->
                <div class="text wow fadeIn" id="third">
                    <!--head-->
                    <div class="head">
                        <h1>
                            <span class="pointColorText">3.</span> Engensis in ALS
                        </h1>
                    </div>
                    <!--//head-->
                    <p>
                        Amyotrophic Lateral Sclerosis (ALS), more commonly known as Lou Gehrig’s disease, is a
                        progressive
                        and fatal neuromuscular disease. ALS is characterized by the destruction of motor neurons
                        necessary
                        for the mobility muscles. There is no known cause nor identified cure for ALS.
                    </p>
                    <p>
                        16,583 patients are identified as having definite ALS in the US and the estimated prevalence of
                        the
                        disease is 5.2 per 100,000. (National ALS Registry, United States, 2015)
                    </p>
                    <p>
                        Engensis is under development to target ALS. When Engensis is injected along the peripheral
                        nerves
                        and their branches, the localized production of HGF may protect nerves and promote the growth of
                        neurons while also ameliorating atrophic conditions.
                    </p>
                    <p>
                        The US FDA granted <b>orphan drug</b> and <b>fast track designations</b> for Engensis for the
                        potential treatment
                        of ALS. With IND approved from the FDA, Phase II clinical trial of Engensis-ALS is in
                        preparation.
                    </p>
                </div>
                <!--//text-->
                <!--safety-->
                <div class="vm202Table wow fadeIn">
                    <h2>
                        <span class="pointColorText">Safety</span>
                    </h2>
                    <!--image-->
                    <div class="vm202Table wow fadeIn" data-wow-delay=".2s">
                        <img src="img/engensis_safety3_pc.svg" class="pc" />
                        <img src="img/engensis_safety3_mobile.svg" class="mobile" />
                    </div>
                    <!--//image-->
                </div>
                <!--//safety-->
                <!--text-->
                <div class="text wow fadeIn">
                    <p>
                        There have been no serious adverse events directly attributed to Engensis in the Phase I/II
                        trial,
                        except for grade 1 injection site reactions, which are resolved uneventfully. Also, the encoded
                        gene
                        is indigenous, eliminating immune response concerns possibly attached with other gene therapies.
                    </p>
                </div>
                <!--//text-->
                <!--eff-->
                <div class="vm202Table wow fadeIn">
                    <h2>
                        <span class="pointColorText">Efficacy</span>
                    </h2>
                    <!--image-->
                    <div class="vm202Table wow fadeIn" data-wow-delay=".2s">
                        <img src="img/engensis_efficacy3_pc.svg" class="pc" />
                        <img src="img/engensis_efficacy3_mobile.svg" class="mobile" />
                    </div>
                    <!--//image-->
                </div>
                <!--//eff-->
                <!--text-->
                <div class="text wow fadeIn">
                    <p>
                        ALSFRS-R (evaluating overall ALS conditions) and MRC Scale (evaluating muscle strength) from the
                        Phase I/II trial showed a trend that the ALS conditions were stabilized for 3 months after the
                        1st
                        injection of Engensis.
                    </p>
                </div>
                <!--//text-->
                <!--divider-->
                <div class="divider"></div>
                <!--//divider-->
                <!--text-->
                <div class="text wow fadeIn" id="fourth">
                    <!--head-->
                    <div class="head">
                        <h1>
                            <span class="pointColorText">4.</span> Engensis in CAD
                        </h1>
                    </div>
                    <!--//head-->
                    <p>
                        Coronary artery disease (CAD), also known as Ischemic heart disease (IHD) occurs when one or
                        more of
                        the coronary arteries are narrowed or occluded, resulting in the decrease of blood supply to the
                        heart muscle.
                    </p>
                    <p>
                        IHD is the third leading cause of death worldwide. The disease recurs to 30% of the patients who
                        have received surgical procedures (PCI, CABG) and medication, which are the most common
                        treatments.
                        Furthermore, about 10% of the patient population do not respond to medication and cannot receive
                        surgery.
                    </p>
                    <p>
                        Engensis promotes blood vessel formation in the ischemic area by HGF-based angiogenesis.
                        HGF-based
                        angiogenesis also has advantage in cardiac muscle function improvement through the suppression
                        of
                        apoptosis and cardiac fibrosis following myocardial infarction, a form of CAD.
                    </p>
                    <p>
                        Helixmith is preparing phase II clinical trial in Korea using Engensis in patients who had
                        percutaneous coronary intervention (PCI) for the anterior wall infarction of the left ventricle
                        following acute myocardial infarction.
                    </p>
                </div>
                <!--//text-->
                <!--safety-->
                <div class="vm202Table wow fadeIn">
                    <h2>
                        <span class="pointColorText">Safety</span>
                    </h2>
                    <!--image-->
                    <div class="vm202Table wow fadeIn" data-wow-delay=".2s">
                        <img src="img/engensis_safety4_pc.svg" class="pc" />
                        <img src="img/engensis_safety4_mobile.svg" class="mobile" />
                    </div>
                    <!--//image-->
                </div>
                <!--//safety-->
                <!--text-->
                <div class="text wow fadeIn">
                    <p>
                        No unexpected serious adverse events (SAEs) or deaths were observed during the follow-up period.
                        HGF
                        protein levels in plasma remained stable throughout the study without any noticeable change, and
                        antibodies to human HGF proteins expressed by VM202 injection were not detected in serum during
                        the
                        follow-up period.
                    </p>
                </div>
                <!--//text-->
                <!--eff-->
                <div class="vm202Table wow fadeIn">
                    <h2>
                        <span class="pointColorText">Efficacy</span>
                    </h2>
                    <!--image-->
                    <div class="vm202Table wow fadeIn" data-wow-delay=".2s">
                        <img src="img/engensis_efficacy4_pc.svg" class="pc" />
                        <img src="img/engensis_efficacy4_mobile.svg" class="mobile" />
                    </div>
                    <!--//image-->
                </div>
                <!--//eff-->
                <!--text-->
                <div class="text wow fadeIn">
                    <p>
                        Engensis was shown to significantly help improvement in myocardial perfusion, wall thicknesses,
                        and
                        wall motion in patients with angina pectoris.
                    </p>
                </div>
                <!--//text-->
            </div>
        </div>
        <!--//1-->
        <!--divider-->
        <div class="divider"></div>
        <!--//divider-->
        <!--footer-->
        <div class="footer">
            <div class="menus">
                <a href="#">
                    Privacy Policy
                </a>
                /
                <a href="careers.html">
                    Careers
                </a>
            </div>
            <div class="info">
                <div class="left">
                    5th Fl. Bldg. 203 Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 00826, Republic of
                    Korea<br>
                    Tel. 82.2.2102.7200 / Fax. 82.2.873.8022 / Email. hxir@helixmith.com
                </div>
                <div class="right">
                    Copyright © 2019 Helixmith Co., Ltd. All Rights Reserved.
                </div>
            </div>
        </div>
        <!--//footer-->
    </div>
    <!--//wrapper-->
    <!--mobile Menu-->
    <div id="mobileMenu">
        <ul>
            <li>
                <a href="about_1.html">
                    Our Company
                </a>
            </li>
            <li>
                <a href="about_2.html">
                    Team Member
                </a>
            </li>
            <li>
                <a href="about_3.html">
                    Locations
                </a>
            </li>
            <li>
                <a href="vm202.html">
                    Engensis Overview
                </a>
            </li>
            <li>
                <a href="vm202_dpn.html">
                    Engensis
                </a>
            </li>
            <li>
                <a href="platform.html">
                    Platform & Technology
                </a>
            </li>
            <li>
                <a href="botanicals.html">
                    CERESMITH
                </a>
            </li>
            <li>
                <a href="#">
                    News
                </a>
            </li>
            <li>
                <a href="careers.html">
                    Careers
                </a>
            </li>
            <li>
                <div class="button" id="hidePanel">
                    <img src="img/close_ico.svg" />
                </div>
            </li>
        </ul>
    </div>
    <!--//mobile Menu-->
    <!--js-->
    <script src="js/wow.js"></script>
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.11.1/jquery.min.js"></script>

    <script>
        wow = new WOW(
            {
                animateClass: 'animated',
                offset: 100,
                callback: function (box) {
                    console.log("WOW: animating <" + box.tagName.toLowerCase() + ">")
                }
            }
        );
        wow.init();

        $(document).ready(function () {

            $("#showPanel").click(function () {
                $("#mobileMenu").show();
            });

            $("#hidePanel").click(function () {
                $("#mobileMenu").hide();
            });

        });
    </script>
    <!--//js-->
</body>

</html>